Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Total Non-Current Liabilities (2016 - 2018)

Assembly Biosciences has reported Total Non-Current Liabilities over the past 4 years, most recently at $38.9 million for Q4 2018.

  • Quarterly results put Total Non-Current Liabilities at $38.9 million for Q4 2018, down 8.84% from a year ago — trailing twelve months through Dec 2018 was $38.9 million (down 8.84% YoY), and the annual figure for FY2018 was $38.9 million, down 8.84%.
  • Total Non-Current Liabilities for Q4 2018 was $38.9 million at Assembly Biosciences, roughly flat from $38.9 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for ASMB hit a ceiling of $55.4 million in Q1 2017 and a floor of $11.1 million in Q4 2016.
  • Median Total Non-Current Liabilities over the past 4 years was $38.9 million (2018), compared with a mean of $29.7 million.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 377.93% in 2017 and later dropped 26.49% in 2018.
  • Assembly Biosciences' Total Non-Current Liabilities stood at $11.6 million in 2015, then decreased by 4.14% to $11.1 million in 2016, then soared by 283.93% to $42.7 million in 2017, then fell by 8.84% to $38.9 million in 2018.
  • The last three reported values for Total Non-Current Liabilities were $38.9 million (Q4 2018), $38.9 million (Q3 2018), and $40.2 million (Q2 2018) per Business Quant data.